New drug combo aims to fight advanced cancers in first human trial
NCT ID NCT07607678
First seen May 27, 2026
Summary
This early-phase study tests a new experimental drug (BI 3819026) alone and with another drug (ezabenlimab) in adults with advanced solid cancers that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. About 60 participants will receive different doses and be monitored for up to 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clínica Universidad de Navarra
NOT_YET_RECRUITINGPamplona, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hackensack University Medical Center
NOT_YET_RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clinico Universitario de Valencia
RECRUITINGValencia, 46010, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital
RECRUITINGTokyo, Chuo-ku, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
NOT_YET_RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
New York University Langone Medical Center
NOT_YET_RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
SCRI Oncology Partners
NOT_YET_RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Cancer Center
NOT_YET_RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.